Nektar Therapeutics NKTR Operating Cash Flow
Operating Cash Flow at other companies
Other financials
Where this comes from
Reported directly by Nektar Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities.
The official record: Nektar Therapeutics’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →
Ask your AI about Nektar Therapeutics's operating cash flow.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Nektar Therapeutics's operating cash flow?
- Nektar Therapeutics (NKTR) reported operating cash flow of -$44.3M in Q1 2026.
- How has Nektar Therapeutics's operating cash flow changed year-over-year?
- Nektar Therapeutics's operating cash flow increased by 9.7% year-over-year, from -$49.05M to -$44.3M.
- What is the long-term trend for Nektar Therapeutics's operating cash flow?
- Over 4 years (2021 to 2025), Nektar Therapeutics's operating cash flow has grown at a -15.7% compound annual growth rate (CAGR), from -$412.66M to -$208.51M.
- What does operating cash flow mean?
- Total cash generated by or used in core business operations — the single most important cash flow metric for assessing business health.